uploads/2018/10/Immunology.png

Stelara and Simponi Drive Johnson & Johnson’s Immunology Business

By

Updated

Revenue trends

Johnson & Johnson’s (JNJ) immunology business generated revenue of $3.4 billion in the third quarter compared to $3.3 billion in the third quarter of 2017, reflecting ~3.9% YoY (year-over-year) growth.

Johnson & Johnson’s immunology business generated revenues of $2.4 billion and $998.0 million from sales in the US and international markets, respectively, in the quarter, reflecting rises of ~0.8% and ~17.6% YoY, respectively.

Article continues below advertisement

The immunology business’s net revenue for the first nine months of the year totaled $9.8 billion, reflecting ~6.8% YoY growth. The revenue growth of Johnson & Johnson’s immunology business could boost the share price of the iShares Russell 1000 Value ETF (IWD). Johnson & Johnson makes up ~2.34% of IWD’s total portfolio holdings.

Remicade’s revenue trends

Johnson & Johnson’s Remicade generated revenue of $1.4 billion in the third quarter, including revenues of $987.0 million and $292.0 million from its sales in the US and international markets, respectively.

In the third quarter, Remicade’s net sales witnessed a ~16.3% YoY fall. In the US and international markets, Remicade witnessed an ~18.2% YoY fall and a 2.5% YoY rise.

Article continues below advertisement

Simponi’s revenue trends

Simponi reported revenue of $536.0 million in the third quarter compared to $476.0 million in the third quarter of 2017, reflecting ~12.6% YoY growth.

In the third quarter, in the US and international markets, Simponi generated revenues of $281.0 million and $255.0 million, respectively, compared to $242.0 million and $234.0 million, respectively, in the third quarter of 2017, reflecting ~16.1% and 9.0% YoY rises.

Simponi’s net revenue for the first nine months of 2018 totaled $1.6 billion, reflecting ~19.3% YoY growth.

In the psoriatic arthritis biologics market, Simponi and Remicade face stiff competition from AbbVie’s (ABBV) Humira, Amgen’s (AMGN) Enbrel, and UCB’s Cimzia. Amgen’s Enbrel and AbbVie’s Humira reported revenues of $1.25 billion and $5.2 billion, respectively, in the second quarter, reflecting an ~11% YoY fall and a 10% YoY rise.

Article continues below advertisement

Stelara’s revenue trends

Johnson & Johnson’s Stelara generated revenue of $1.3 billion in the third quarter, reflecting ~16.5% YoY growth.

In the US and international markets, in the third quarter, Stelara generated revenues of $889.0 million and $421.0 million, respectively, compared to $800.0 million and $324.0 million, respectively, in the third quarter of 2017, reflecting ~11.1% and 29.0% YoY rises. in the international markets, Stelara witnessed ~33.0% YoY operational growth.

Stelara’s net revenue in the first nine months of 2018 totaled $3.7 billion compared to $2.9 billion in the same period of the previous year, reflecting ~26.7% YoY growth. In the US and international markets, Stelara generated net revenues of $2.46 billion and $1.25 billion, respectively, reflecting 21.4% and 38.6% YoY rises.

Advertisement

More From Market Realist